Cure Mucolipidosis
Nonprofit profile at a glance
- EIN
- 863929222
- IRS 990-EZ coverage
- 2022–2024
- Forms available
- Form 990-EZ 2024, Form 990-N 2021
- Location
- Belleville, IL, USA
- Phone
- 3146407844
- Rating confidence
- Limited
- Sector
- Research Institutes and/or Public Policy Analysis
Reported finances
- Revenue
- $67,567
- Expenses
- $9,669
- Assets
- $97,169
Source: IRS Form 990-EZ. Selected filing: tax year 2024. Amounts in USD.
Leadership & pay
9 people listed
Executive titles in this filing
- JACQUELINE JAMES (PRESIDENT)
People named in this filing
- JACQUELINE JAMES (PRESIDENT)
- JENNY NOBLE (SECRETARY)
- KEVIN GATES (TREASURER)
Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.
Source: IRS Form 990-EZ. Selected filing: tax year 2024. Names and roles reflect this filing, not necessarily current officeholders.
Overview
Mission
Cure mucolipidosis is a global organization that is committed to the identification and treatment of mucolipidosis through education, advocacy and research.
What it reported doing in 2024
We co-funded a research project to look at drug uptake in mucolipidosis to find out why patients seem to have less response to pain medication. Worked to secure an agreement with umass to start the journey of gene therapy for mucolipidosis.
Operating model
- Revenue model
- Donor-supported. 100% of the money available for current operations came from contributions and gifts.
- Distribution model
- Cannot be determined from the filing. The filing does not provide enough consistent spending detail to tell whether the nonprofit works directly or through others.
The verdict
- The available evidence is not sufficient to produce an overall rating for this filing. This is not a warning sign.
Rating breakdown
- Financial Efficiency: NotEnoughData
- Transparency & Controls: 82
- Sustainability: 80
- Growth: 20
Detailed rating inputs
Financial Efficiency
- Mission deployment rate: Limited
- Program expense ratio: Limited
Transparency & Controls
- Consistency checks: 100%; rating input score 100; 52nd percentile among comparable filings
- Major donor itemization: Limited
Sustainability
- Operating margin: 85.7%; rating input score 98; 98th percentile among comparable filings
- Total-asset coverage ratio: 10.05; rating input score 92; 92nd percentile among comparable filings
- Liabilities to assets ratio: Limited
- Officer compensation ratio: 0%; rating input score 56; 56th percentile among comparable filings
Growth
- Program expense growth: -87.2% per year; rating input score 0; 4th percentile among comparable filings
- Revenue growth: -37.9% per year; rating input score 0; 8th percentile among comparable filings
- Asset growth: 60.8% per year; rating input score 100; 97th percentile among comparable filings
Details
- Where the money goes: Financial trends and filed revenue, expense, asset, and liability detail
- Governance: Filed governance answers
- Accomplishments: 1 filed program accomplishment
- Leadership: top reported pay $0 · 9 people listed
- Consistency: 5 of 5 current checks pass
- Schedules: 2 filed schedules
- Filing history: 3 filing years from 2022 to 2024
- Contacts: How to reach this organization
- Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
- People: Everyone the filings name, and which of them the filings identify by more than a name.
Key Signals
Signals prioritize questions for review. They are not findings of misconduct.
- High — Growth: Program expense growth scored 0/100.
- High — Growth: Revenue growth scored 0/100.
- Review — Sustainability: Officer compensation ratio scored 56/100.